The team, led by Jinping Dou and Shuang Wei, who contributed equally to the work, with corresponding authors Xingjian Liu and Yinü Li, worked from GETV-BJ0304, an attenuated strain previously isolated by the group. Attenuated strains are attractive backbones for reverse genetics systems because they can be manipulated under less stringent containment considerations while still recapitulating core features of alphavirus biology. Using a seamless cloning method, the researchers assembled the complete viral genome rapidly, avoiding the restriction-site scars and extraneous sequences that plague older ligation-based approaches. Seamless assembly matters in this context because alphavirus genomes are compact and densely packed; even small insertions of nonviral sequence at junction sites can alter replication kinetics and confound downstream experiments.

Getah virus belongs to the Alphavirus genus within the Togaviridae family, a group characterized by a positive-sense, single-stranded RNA genome of roughly 11 to 12 kilobases. The genome is organized into two open reading frames: the nonstructural polyprotein encoded at the 5′ end, which supplies the replication machinery, and the structural polyprotein at the 3′ end, which is translated from a subgenomic RNA. This subgenomic RNA is produced from an internal promoter, conventionally called the 26S subgenomic promoter (26SGP), which drives very high levels of structural protein expression during infection. That architecture creates two natural insertion points for a reporter gene, and each comes with distinct trade-offs that the Beijing team set out to quantify.

The first strategy exploits the 2A self-cleaving peptide, a short sequence, originally described in picornaviruses, that induces ribosomal skipping during translation. When a reporter gene such as enhanced green fluorescent protein (EGFP) is fused to a viral polyprotein through a 2A sequence, the translating ribosome ‘skips’ a peptide bond at the 2A motif, releasing the reporter as a largely separate protein while leaving the viral polyprotein essentially intact. The elegance of this approach is that the reporter is expressed from the same mRNA as the viral protein, so reporter output tracks faithfully with viral gene expression, and the viral genome length increases only modestly. The second strategy inserts an additional copy of the 26S subgenomic promoter upstream of the reporter gene, creating a second subgenomic RNA dedicated to reporter translation. This duplicated-promoter design can drive very high reporter expression, but it adds substantial sequence to the genome and introduces an extra promoter element that the viral replication machinery must recognize and that recombination can act upon.

Which strategy wins has often been assumed rather than tested, particularly for attenuated alphavirus backbones where genomic flexibility may differ from that of virulent laboratory strains. The researchers constructed reporter viruses carrying EGFP through both routes and then subjected the resulting recombinants to a battery of characterization assays. The results were decisive: for the GETV-BJ0304 backbone, the 2A self-cleaving peptide strategy proved highly efficient and stable. The recombinant virus, designated GETV-2A/EGFP, displayed high infection efficiency and, importantly, maintained its reporter over serial passages, a property that many reporter alphaviruses lose as deletion or mutation of the foreign sequence confers a replicative advantage.

Genetic stability is the quiet battleground of reporter virology. A reporter virus that sheds its fluorescent cargo after a few rounds of replication is worse than useless, because it silently biases experiments: the cells that remain fluorescent are those infected by the fittest, reporter-retaining variants, which may not represent the population the researcher intends to study. By demonstrating that GETV-2A/EGFP retains high-level EGFP expression through extended passaging, the study provides a technical platform whose fluorescence can be taken as a reliable proxy for infection. That reliability underpins quantitative applications ranging from neutralization assays and antiviral screening to single-cell analyses of viral spread, where fluorescence intensity and infected-cell counts feed directly into the analysis.

The comparison also carries broader lessons for alphavirus reverse genetics. The 26S promoter duplication strategy, while capable of strong expression, imposes a larger genomic burden and creates duplicated promoter sequences that are intrinsically recombination-prone. In an attenuated backbone, where replication fidelity and genomic tolerance may already be strained, that burden appears to be decisive. The 2A approach, by contrast, keeps the added sequence short and avoids duplicating regulatory elements, aligning reporter expression with the natural translational output of the viral polyprotein. The finding does not necessarily generalize to every alphavirus or every backbone, but it offers an evidence-based default for researchers constructing reporter clones in attenuated strains, replacing intuition with head-to-head data.

Why does Getah virus warrant this level of technical investment? The virus circulates in a transmission cycle involving mosquitoes and vertebrate hosts, and it has caused notable epizootics in horses, characterized by fever, edema, and urticarial rash, as well as reproductive disease and neurological signs in piglets. Although GETV is not currently a major human pathogen, its recent outbreaks and demonstrated potential for increased virulence have placed it alongside other arboviruses as a public-safety concern. Climate change, expanding mosquito vector ranges, and intensification of livestock production all create conditions favorable to emergence. A robust reverse genetics system is the prerequisite for dissecting which viral proteins and RNA elements drive host range, virulence, and transmission, and for rationally designing attenuated vaccine candidates or antiviral targets rather than discovering them by trial and error.

The platform described in the study enables exactly that dissection. With a stable fluorescent reporter embedded in an otherwise authentic viral genome, researchers can monitor replication in real time, quantify infection in the presence of interfering RNAs or candidate drugs, and screen host genes for factors that restrict or support GETV invasion. The authors frame the system as a crucial technical platform for in-depth analysis of GETV replication and pathogenic mechanisms, as well as for exploring new strategies that help the host resist viral invasion. In practical terms, that means the clone can serve as the starting point for mutant libraries, for structure-function studies of the nonstructural proteins, and for testing how specific mutations alter tropism in mosquito and mammalian cells.

The work, funded by China’s National Key Research and Development Program, the National Natural Sciences Foundation of China, the Agricultural Science and Technology Innovation Program, and the Central Public-interest Scientific Institution Basal Research Fund, arrives as an open-access publication, making the construction logic and characterization data available to laboratories worldwide. As arboviruses continue to test the boundaries of veterinary and public health preparedness, tools of this kind, a rapidly assembled infectious clone paired with a validated, stable reporter strategy, convert an emerging pathogen from an opaque threat into an experimentally tractable one. For Getah virus, the 2A-based design now stands as the benchmark against which future reporter constructs will be measured.

Subject of Research: Construction and comparison of reporter gene insertion strategies in Getah virus reverse genetics systems

Article Title: Comparison and characterization of construction strategies for Getah virus infectious clones with stable, high-level expression of reporter gene

Article References: Dou, J., Wei, S., Gao, X., Wu, T., Zhao, Z., Zhang, Z., Liu, X., & Li, Y. (2026). Comparison and characterization of construction strategies for Getah virus infectious clones with stable, high-level expression of reporter gene. Cellular and Molecular Life Sciences. https://doi.org/10.1007/s00018-026-06457-x

Image Credits: AI Generated

DOI: 10.1007/s00018-026-06457-x

Keywords: Getah virus, alphavirus, reverse genetics, infectious clone, reporter gene, EGFP, 2A self-cleaving peptide, subgenomic promoter, arbovirus, genetic stability, viral replication, veterinary virology

The SAP domain is a compact protein module originally described in host nuclear proteins, where it mediates binding to RNA and chromatin-associated structures. In FMDV Lpro, this region sits within the N-terminal portion of the enzyme and has been implicated in the proteinase’s ability to interfere with host cell functions, including the transcriptional activation of interferon-stimulated genes. Lpro carries out a dual life for the virus: on one hand it cleaves the host translation initiation factor eIF4G to shut down capped host mRNA translation while leaving viral RNA translation intact, and on the other hand it proteolytically removes or disrupts host factors that would otherwise signal the presence of a viral invader. By suppressing the innate immune response, Lpro buys the virus the window of time it needs to replicate to high titers, spread through the animal, and produce the characteristic vesicular lesions of foot-and-mouth disease. The Indian team hypothesized that introducing stable mutations into the SAP domain would blunt this immune suppression, thereby derepressing innate immune genes while ideally preserving the replication functions needed for vaccine production.

To test this hypothesis, the researchers built on an infectious cDNA clone derived from the wild-type FMDV strain Asia1/IND/63/1972, referred to as pAsia-WT. Using reverse genetics, they introduced targeted mutations into the codons encoding the SAP domain of Lpro and attempted to rescue viable virus from transfected cells. Two mutant viruses emerged from this effort, designated pAsia-SAP1 and pAsia-SAP2. The ability to rescue both mutants demonstrated that the SAP domain tolerates a degree of amino acid substitution without abolishing the viral life cycle, an encouraging sign for any attenuation strategy, since a vaccine candidate must replicate sufficiently to elicit immunity.

A central concern with any live attenuated virus is whether the engineered mutations compromise replication in a way that would undermine immunogenicity, or alternatively revert to wild type during propagation. The team therefore compared the growth kinetics and plaque morphology of the two mutants with those of the parental pAsia-WT virus in vitro. Both mutants replicated with kinetics statistically indistinguishable from the wild-type clone, with no significant differences observed across the measured time points, and their plaque phenotypes were likewise comparable. This result indicates that the SAP domain mutations do not impose a measurable fitness cost in cell culture, fulfilling one of the key prerequisites for a practical live vaccine platform.

Genetic stability proved to be the discriminating factor between the two mutants. When the viruses were serially passaged, sequencing revealed that pAsia-SAP2 retained its engineered mutations through twenty passages, a reassuring indicator of genomic stability. pAsia-SAP1, in contrast, showed partial reversion: the mutation at position 56, G56, was preserved, but the engineered change at position 55 reverted back to the wild-type serine, S55. This differential behavior underscores a broader principle of attenuated virus design, namely that the identity of the substituted amino acid and the precise position within the functional domain jointly determine whether an attenuation phenotype will be maintained over successive replication cycles. A mutation that is stable is not merely preferable; it is essential, since reversion during vaccine manufacture or in a vaccinated animal could restore virulence.

The immunological consequences of the mutations were assessed by measuring the transcripts of innate immune response genes in infected cell cultures. Here the two mutants diverged in a revealing way. Cells infected with pAsia-SAP1 showed a pronounced upregulation of innate immune response gene expression compared with the wild-type virus, consistent with the idea that an impaired SAP domain can no longer fully suppress the host’s antiviral transcriptional program. pAsia-SAP2, by contrast, did not produce the same degree of immune gene derepression in vitro. On the surface, this might suggest that SAP1 is the stronger candidate for immune activation, but the in vivo data told a different and more nuanced story.

In the suckling mouse model, a sensitive standard assay for FMDV virulence, pAsia-SAP2 displayed a markedly reduced pathogenicity. Animals inoculated with the SAP2 mutant survived in greater numbers, and those that did succumb did so with delayed mortality, indicating that the virus had lost a substantial portion of its capacity to cause lethal disease. The partial reversion at S55 in SAP1 may help explain why the less stable mutant did not show the same degree of attenuation in animals; restoration of even a single wild-type residue can partially restore the virulence-associated functions of Lpro. Taken together, the data support the authors’ conclusion that mutations in the SAP domain derepress innate immune responses and reduce pathogenicity in a manner that depends critically on the site of mutation and the nature of the substituted amino acids.

The attenuation phenotype was further corroborated in guinea pigs, an established laboratory host for FMDV research. When guinea pigs were inoculated with pAsia-SAP2, the mutant failed to induce detectable viremia, meaning the virus could not establish a systemic blood-borne infection in these animals. This absence of viremia is a strong indication that the SAP2 mutations substantially impair the virus’s ability to progress beyond local replication and disseminate within a mammalian host, a defining feature of FMDV pathogenesis. For a candidate vaccine strain, failure to produce viremia is doubly desirable, because it simultaneously suggests reduced disease potential and a lower probability that the vaccine virus will spread systemically and be shed by immunized animals.

The broader significance of this work lies in the strategy it validates. Rather than deleting entire genes or relying on serial passage to weaken the virus, the researchers targeted a defined virulence determinant with site-directed mutagenesis, preserving replication competence while dismantling immune evasion. Because Lpro sits at the interface of viral replication and innate immune antagonism, tuning this protein offers an unusually elegant attenuation mechanism: the crippled immune evasion means the host mounts an earlier and stronger antiviral response, while the intact replicative machinery ensures the virus still delivers antigen effectively. The demonstration that mutation site and amino acid identity govern both stability and phenotype gives vaccine developers a practical map for engineering the next generation of FMDV vaccine candidates. FMDV circulates as seven distinct serotypes with substantial antigenic diversity, and vaccines based on attenuated strains can, with appropriate matching, deliver broader and more durable immunity than conventional inactivated vaccines, which require high-containment production and provide incomplete cross-protection.

As foot-and-mouth disease continues to menace livestock economies across Asia, Africa, and beyond, the demand for safer, more stable, and more easily manufactured vaccines remains acute. This study, conducted with support from the Department of Biotechnology, Government of India, adds a molecularly precise tool to that effort. By showing that SAP domain mutations in Lpro can render an Asia1 serotype virus attenuated in vivo while preserving its growth properties in vitro and its genetic integrity over serial passage, the ICAR-IVRI team has provided both a candidate platform and a mechanistic insight: the same domain that helps FMDV hide from the immune system can, when disrupted at the right positions, become the virus’s undoing. Future work will need to test protective efficacy and cross-serotype applicability, but the foundational principle demonstrated here, that rational attenuation of a virulence factor can outperform empirical weakening, is likely to inform live attenuated vaccine design well beyond this single pathogen.

Subject of Research: SAP domain mutations in foot-and-mouth disease virus leader proteinase that reduce virulence

Article Title: Mutations in the SAF-A/B, acinus, and PIAS domain reduce the virulence of foot-and-mouth disease virus

Article References: Pyatla, M. K. G., Shekhawat, I., Mundhe, S. S., Elango, S., Periyasamy, T. S. R., Nagargoje H, S., Mahadappa, P., Vijayapillai, U., Krishnaswamy, N., Chaudhuri, P., & Joyappa, D. H. (2026). Mutations in the SAF-A/B, acinus, and PIAS domain reduce the virulence of foot-and-mouth disease virus. Applied Microbiology and Biotechnology. https://doi.org/10.1007/s00253-026-14034-2

Image Credits: AI Generated

DOI: 10.1007/s00253-026-14034-2

Keywords: foot-and-mouth disease virus, FMDV, leader proteinase, SAP domain, virulence, attenuation, innate immunity, reverse genetics, live vaccine, viral pathogenesis, Asia1 serotype, genetic stability